Comparable to cancer in prevalence and costs, rheumatology diseases (autoimmune, musculoskeletal, inflammatory), are the next big chronic disease target. While
Interest in value-based contracts (VBCs) with pharmaceutical manufacturers by healthcare payer/payvider/employer plans is increasing. Focus on ever-higher drug costs is
Whether you manage payer, payvider, Medicare Advantage or employer healthcare plans, high-risk, high-cost chronic autoimmune conditions hide in your population.
Comparable to cancer in prevalence and costs, rheumatology diseases (autoimmune, musculoskeletal, inflammatory), are the next big chronic disease target. While
Interest in value-based contracts (VBCs) with pharmaceutical manufacturers by healthcare payer/payvider/employer plans is increasing. Focus on ever-higher drug costs is
Whether you manage payer, payvider, Medicare Advantage or employer healthcare plans, high-risk, high-cost chronic autoimmune conditions hide in your population.